# TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

> **NCT00144417** · PHASE2 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 433 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)
- **DRUG:** isoniazid

## Key facts

- **NCT ID:** NCT00144417
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-06
- **Final completion:** 2007-12
- **Target enrollment:** 433 (ACTUAL)
- **Last updated:** 2011-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144417, "TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00144417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*